Reference
·Primary source
TFDA accelerated approval pathway timeline (2026-2029)
Q3 2026 target live
The Thai FDA accelerated approval pathway consultation paper (April 2026) outlines Phase II conditional approval for AI-discovered compounds with adaptive trial design, an approach modelled on US FDA Accelerated Approval and EMA Conditional Marketing Authorisation. Target effective date is Q3 2026 but Thai regulatory implementation timelines have historically slipped 6-12 months. A late-2027 effective date still materially compresses time-to-revenue for the first cohort of AI-discovered Thai compounds versus a traditional Phase III pathway. First AI-discovered Thai compounds are projected to clear Phase II conditional approval by 2028-2029.
Figure in context
The Thai FDA accelerated approval pathway consultation paper (April 2026) outlines Phase II conditional approval for AI-discovered compounds with adaptive trial design, an approach modelled on US FDA Accelerated Approval and EMA Conditional Marketing Authorisation. Target effective date is Q3 2026 but Thai regulatory implementation timelines have historically slipped 6-12 months. A late-2027 effective date still materially compresses time-to-revenue for the first cohort of AI-discovered Thai compounds versus a traditional Phase III pathway. First AI-discovered Thai compounds are projected to clear Phase II conditional approval by 2028-2029.
The Thai FDA accelerated approval pathway consultation paper (April 2026) outlines Phase II conditional approval for AI-discovered compounds with adaptive trial design, an approach modelled on US FDA Accelerated Approval and EMA Conditional Marketing Authorisation. Target effective date is Q3 2026 but Thai regulatory implementation timelines have historically slipped 6-12 months. A late-2027 effective date still materially compresses time-to-revenue for the first cohort of AI-discovered Thai compounds versus a traditional Phase III pathway. First AI-discovered Thai compounds are projected to clear Phase II conditional approval by 2028-2029.
Time scope
2026-2029
Source basis
Primary source
Interpretation notes
What this tells you
The Thai FDA accelerated approval pathway consultation paper (April 2026) outlines Phase II conditional approval for AI-discovered compounds with adaptive trial design, an approach modelled on US FDA Accelerated Approval and EMA Conditional Marketing Authorisation. Target effective date is Q3 2026 but Thai regulatory implementation timelines have historically slipped 6-12 months. A late-2027 effective date still materially compresses time-to-revenue for the first cohort of AI-discovered Thai compounds versus a traditional Phase III pathway. First AI-discovered Thai compounds are projected to clear Phase II conditional approval by 2028-2029.
What not to do with it
Pathway targets Phase II conditional approval with adaptive trial design for AI-discovered compounds. Bulk manufacturing tenders at GPO and Siam Bioscience follow first approvals by an estimated 12-18 months.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
NSTDA BIOTEC, Genome Thailand programme, SCB EIC pharma outlook, PReMA industry profile, foreign-partner disclosures
Thailand AI drug discovery activity mix (2027 estimate)
NSTDA BIOTEC; Siriraj Centre of Research Excellence; SCB EIC pharma outlook; PReMA industry profile
Genome Thailand WGS cohort buildout (2024-2027)
Ministry of Higher Education, Science, Research and Innovation; NSTDA Genome Thailand programme; NSTDA annual report
Thailand AI drug discovery operator concentration (2027 estimate)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; Chulalongkorn Health Innovation Hub; Siriraj Centre of Research Excellence; foreign-partner disclosures
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Foreign-pharma Thailand clinical-trial spend (2025-2027)
AstraZeneca Thailand R&D briefings; Roche Thailand personalised healthcare disclosures; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.